The financials
Immunocore Holdings plc by the numbers
Immunocore Holdings plc (IMCR) reported revenue of $107M in Q1 2026 (quarter ended Mar 31, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 100% and net income of $13M (12% of revenue). For the full year FY2025, revenue was $400M (+29% year on year) and net income −$36M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was Sale Of Therapies at $75M, 100% of the disclosed total, well ahead of Collaboration at 0.1%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $107M | $94M | +14% |
| Gross profit | $106M | $93M | +14% |
| Operating income | $7.3M | −$3.6M | to a profit |
| Net income | $13M | $5.0M | +158% |
| Diluted EPS | $0.25 | $0.10 | +150% |
| Product | Revenue | Share |
|---|---|---|
| Sale Of Therapies | $75M | 100% |
| Collaboration | $53K | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $115.9M (+8.7%)
Sale Of Therapies grew +18% year on year
Segment Latestquarter on quarteryear on year
- Sale Of Therapies$115.9M$115.9MQoQ +8.7%year on year +18%+8.7%+18%